
The Allevi Liver dECM promises the fabrication of liver tissue that has a more representative physiological function. The product uses a combination of a type I collagen Allevi bioink for patterning as well as Xylyx Bio’s highly desired liver-specific TissueSpec® ECM to enhance specialized biological response.
Xylyx Bio products for cell culture are obtained from porcine or human tissue sources and processed to various formats, enabling cell culture models that are significantly more predictive of physiology. Their 3D TissueSpec® ECM hydrogels and scaffolds provide support to cell culture models, facilitating the acceleration of drug discovery, development and tissue regeneration.
“We are thrilled to partner with Allevi and share our expertise in tissue-specific ECM,” stated Andrea Nye, Chief Executive Officer at Xylyx Bio. “Recognizing the importance of the native cellular microenvironment, Xylyx Bio harnesses the body’s innate biology in the form of tissue-specific extracellular matrix. By sourcing extracellular matrix from native organs and tissues, Xylyx produces tissue-specific substrates that comprise both the mechanical properties and complex ratios of ECM components specific and unique to each tissue and organ type.”
Founded in 2014, Allevi claims that its “mission is to provide users the ability to design, engineer, and manufacture 3D tissue.” To deliver important building blocks and provide users with the best experience possible to drive new scientific discoveries, Allevi is hopeful that the new dECM bioink will provide scientists a revolutionary approach that allows scientists to print 3D tissue structures with biochemical and mechanical features inherent in human physiology.
[Images: Allevi and Xylyx Bio]
Xylyx Bio’s Co-founder and Chief Strategy Officer, John O’Neil, added that a “deeper understanding of the comprehensive nature of tissues and cells and their interaction with the cellular microenvironment – that is, the extracellular matrix – holds great promise to lead to a paradigm shift in 3D bioprinting, allowing researchers to study physiologic activity of cells in vitro towards a better understanding of disease and development of more effective drugs and treatments.”
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
3D Printing News Briefs, February 8, 2025: Partnership, Post-Processing, & More
We’re starting off today’s 3D Printing News Briefs with business news: Xact Metal shipped its 150th 3D printer and achieved its second highest quarterly order revenue, while Fastech announced a...
Stratasys Secures $120M Investment from Fortissimo Capital Amid Pressure from Bambu Lab
Stratasys Ltd. (NASDAQ: SSYS) has announced a $120 million investment from Fortissimo Capital, an Israeli private equity firm. The deal involves the direct purchase of 11.65 million newly issued shares...
AscendArc Emerges from Stealth with $4M and a 3D Printing Deal
Chris McLain is no stranger to satellites. His experience as a principal engineer at SpaceX, where he worked on Starlink, helped shape the future of global connectivity. Now, he’s taking...
Toyota Joins Japan’s Space Race with $44M Rocket Investment in Interstellar
Toyota is backing Japan’s rocket ambitions with a ¥7 billion ($44.3 million) investment in Interstellar Technologies as part of its Series F funding round. Interstellar, a company aiming to make...